| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/18/2002 | WO2001088134A3 Novel human lipocalin homologs and polynucleotides encoding the same |
| 07/18/2002 | WO2001087980A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 07/18/2002 | WO2001087322A3 Peptide pharmaceutical formulations |
| 07/18/2002 | WO2001085790A3 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 07/18/2002 | WO2001085788A3 Human ion channels |
| 07/18/2002 | WO2001085783A3 Nucleic acids encoding polypeptides related to the alpha subunit of the glycoprotein hormone family and methods of use thereof |
| 07/18/2002 | WO2001084149A3 Diagnostics and therapeutics for macular degeneration-related disorders |
| 07/18/2002 | WO2001083749A3 Gene and sequence variation associated with sensing carbohydrate compounds and other sweeteners |
| 07/18/2002 | WO2001083518A3 Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same |
| 07/18/2002 | WO2001083503A3 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| 07/18/2002 | WO2001082932A3 Methods and compositions for enhancing cellular function through protection of tissue components |
| 07/18/2002 | WO2001081590A3 Protein phosphatases |
| 07/18/2002 | WO2001081544A3 Identification and uses of a hyaluronan receptor |
| 07/18/2002 | WO2001081408A3 G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same |
| 07/18/2002 | WO2001081377A3 Integrin/adhesion antagonists |
| 07/18/2002 | WO2001079468A3 Drug metabolizing enzymes |
| 07/18/2002 | WO2001079282A3 Molecules associated with human reproduction |
| 07/18/2002 | WO2001078789A3 Poliovirus replicons encoding therapeutic agents and uses thereof |
| 07/18/2002 | WO2001072822A3 Genes involved in intestinal inflammatory diseases and use thereof |
| 07/18/2002 | WO2001068839A9 Regulation of human lipoxin a4 receptor-like protein |
| 07/18/2002 | WO2001068705A3 Il-17 receptor like molecules and uses thereof |
| 07/18/2002 | WO2001066747A3 Proteins named fctrx and nucleic acids encoding same |
| 07/18/2002 | WO2001062920A3 Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| 07/18/2002 | WO2001061019A9 A dominant selectable marker for gene transformation and disruption in yeasts |
| 07/18/2002 | WO2001060400B1 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 07/18/2002 | WO2001055309A3 Nucleic acids, proteins, and antibodies |
| 07/18/2002 | WO2001055304A3 Nucleic acids, proteins, and antibodies |
| 07/18/2002 | WO2001051520A9 Nogo receptor-mediated blockade of axonal growth |
| 07/18/2002 | WO2001049295A9 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 07/18/2002 | WO2001044514A3 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 07/18/2002 | WO2001037869A9 Vaccine compositions |
| 07/18/2002 | WO2001036477A3 Inhibition of abc transporters by transmembrane domain analogs |
| 07/18/2002 | WO2001032217A3 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| 07/18/2002 | WO2001012668A9 Cathelicidin-derived peptides with broad spectrum antimicrobial activity |
| 07/18/2002 | WO2001008717A9 Controlled release implantable devices |
| 07/18/2002 | WO2001005834A9 Human tumor necrosis factor receptors tr13 and tr14 |
| 07/18/2002 | WO2000078972A9 Regulation with binding cassette transporter protein abc1 |
| 07/18/2002 | WO2000059533A9 Use of asparaginase and glutaminase to treat autoimmune disease and graft versus host disease |
| 07/18/2002 | US20020095135 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| 07/18/2002 | US20020095108 Photoreduction method for hemoglobin-visicle |
| 07/18/2002 | US20020095030 Nucleotide sequences coding preferfential polypeptides for use in the treatment of apotosis defects |
| 07/18/2002 | US20020095025 Isolation and uses of caveolae |
| 07/18/2002 | US20020095024 B7-related nucleic acids and polypeptides useful for immunomodulation |
| 07/18/2002 | US20020095023 Membrane protein for use in the treatment of allergies, parkinson's, alzheimer's and apoptitic defects |
| 07/18/2002 | US20020095022 Polypeptide for use in the treatment of cancer and sexual disorders |
| 07/18/2002 | US20020095001 Administering a compound selected from histamine, histamine dihydrochloride, histamine diphosphate, other histamine salts, esters, prodrugs, H2 receptor agonists, serotonin, NADPH oxidase inhibitor, and 5HT agonist to cure skin damage |
| 07/18/2002 | US20020094998 Methods and compositions for treatment of ocular neovascularization and neural injury |
| 07/18/2002 | US20020094966 Inhibition of the gene expression or biological activity of the 88 KDa glycoprotein autocrine growth and tumorigenicity stimulator by antisense oligonucleotides and neutralizing antibodies; antitumor, -carcinogenic agents |
| 07/18/2002 | US20020094958 Administering peptidyl diazomethylketones, peptidyl semicarbazones, and diazoacetyl peptidyl alkyl esters of given formula; selective antagonists for cathepsin enzymes; treating neurodegenerative disorders |
| 07/18/2002 | US20020094957 Inhibits the polymerization of amyloid beta peptide; treating or preventing amyloidosis |
| 07/18/2002 | US20020094956 As well as animal model for kidney disease, a mouse that does not express a normal collagen type 4 composition in the glomerular basement membrane |
| 07/18/2002 | US20020094955 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 07/18/2002 | US20020094954 Nucleic acids comprising the neuregulin-1-associated gene 1 (NRG1AG1) |
| 07/18/2002 | US20020094953 Nucleic acids, proteins, and antibodies |
| 07/18/2002 | US20020094952 Human therapeutic uses of BPI Protein products |
| 07/18/2002 | US20020094951 Dental remedies containing pth |
| 07/18/2002 | US20020094949 Synergic neuroprotective action against oxidative stress when used with a formulation of pyruvate, antioxidant and fatty acids |
| 07/18/2002 | US20020094948 To treat anemias or hemodialysis patients; individual dosage forms |
| 07/18/2002 | US20020094947 By administering with the excitatory opioid receptor antagonist nalmefene |
| 07/18/2002 | US20020094576 Material and methods relating to a novel retrovirus |
| 07/18/2002 | US20020094561 Peptide; for use in the treatment of tumors, metabolic and autoimmune disease |
| 07/18/2002 | US20020094560 Peptide; for use in human therapeutics and diagnostics; for use in treatment of inflammation, cancer, arteriosclerosis, and psoriasis |
| 07/18/2002 | US20020094558 Nuclelotide sequences coding membrane protein for use in human therapeutics and diagnostics |
| 07/18/2002 | US20020094546 Detecting platelet derived growth factor in sample; obtain sample, incubate with preferential binding agent, detect bound antigen |
| 07/18/2002 | US20020094534 Methods for immuno-detection of epitopes on molecules and for detection of interactions of molecules via fluorescent dyes |
| 07/18/2002 | US20020094340 Chlamydia antigens and corresponding dna thereof |
| 07/18/2002 | US20020094339 Methods for treating mammary gland disorders |
| 07/18/2002 | US20020094336 Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis |
| 07/18/2002 | US20020094334 Using variant of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between A and B chains; treatment of human immunodeficiency virus |
| 07/18/2002 | US20020094333 Administration of substance which induces active pathogen replication in cell latently infected with HIV and anti-pathogen drug |
| 07/18/2002 | US20020094330 Lytic enzyme produced by bacteria being infected with a bacteriophage specific for said bacteria and carrier for delivering enzyme to eye |
| 07/18/2002 | US20020094327 Increasing concentration of a SDF-1 alpha protein or SDF-1 alpha agonist in target tissue |
| 07/18/2002 | US20020094326 Treating tissue with phosphodiesterase inhibitor compound and administering exogenous nucleic acid |
| 07/18/2002 | US20020094324 Gene therapy for restenosis using an adenoviral vector |
| 07/18/2002 | US20020094323 Administration of reactive oxygen species inhibitor or scavenger and at least one monocyte maturation-promoting agent |
| 07/18/2002 | US20020094319 Lytic enzyme produced by bacteria infected with a bacteriophage specific for that bacteria and a carrier; for treating bacterial infections of the mouth or teeth; anticaries agent |
| 07/18/2002 | US20020094318 Dispersible dry powder of a therapeutic agent such as insulin with an aerogel particle which is soluble in human pulmonary surfactant, such as sugars and carbohydrates |
| 07/18/2002 | US20020092539 Hair clip |
| 07/18/2002 | DE10102048A1 Use of active antithrombin III having endothelial cell proliferation inhibitory activity for combating diseases associated with angiogenesis, e.g. retinopathy, neuropathy, leprosy and cancer |
| 07/18/2002 | DE10100588A1 Inhibiting expression of target genes, useful e.g. for treating tumors, by introducing into cells two double-stranded RNAs that are complementary to the target |
| 07/18/2002 | DE10100280A1 DNA-Sequenzen, codierend für ein Apoptose-Signaltransduktionsprotein DNA sequences encoding an apoptosis-Signaltransduktionsprotein |
| 07/18/2002 | DE10065475A1 Use of intermediate-conductance potassium channel proteins for the diagnosis, prevention and treatment of disorders associated with disturbed keratinocyte activity, especially psoriasis |
| 07/18/2002 | DE10059631A1 T-Zellepitope des Papillomavirus L1-und E7-Proteins und ihre Verwendung in Diagnostik und Therapie T cell epitopes of the papillomavirus L1 and E7 protein and their use in diagnostics and therapy |
| 07/18/2002 | CA2776023A1 Fumaric acid amides |
| 07/18/2002 | CA2444637A1 Hybrid peptides for treatment of bacteremia and septicemia |
| 07/18/2002 | CA2437024A1 Compositions for treatment of hemorrhaging with activated factor viia in combination with fibrinogen |
| 07/18/2002 | CA2436876A1 Transcriptional mediators of blood vessel development and endothelial differentiation |
| 07/18/2002 | CA2434793A1 Ancillary composition for the preparation of committed mature dendritic cells |
| 07/18/2002 | CA2434739A1 Nucleotide sequences and protein(s) encoded by such nucleotides for modulation of apoptosis |
| 07/18/2002 | CA2434672A1 Sfrp and peptide motifs that interact with sfrp and methods of their use |
| 07/18/2002 | CA2434567A1 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 07/18/2002 | CA2434543A1 Inhibition of pathological angiogenesis in vivo |
| 07/18/2002 | CA2434431A1 Generation and/or reduction of new lung tissue in an affected lung, by modulation of the wnt-pathway |
| 07/18/2002 | CA2434330A1 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| 07/18/2002 | CA2434269A1 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| 07/18/2002 | CA2434171A1 Therapeutic modulation of the tumor inflammatory response |
| 07/18/2002 | CA2434170A1 A device and a method for dispensing at least two mutually reactive components |
| 07/18/2002 | CA2434042A1 Asip-related proteins |
| 07/18/2002 | CA2433742A1 Proteins and nucleic acids encoding same |
| 07/18/2002 | CA2433688A1 Extractive purification of lipopeptide antibiotics |